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Abstract The 1998 Australian Measles Control Campaign had as its aim improved immunization coverage among
children aged 1–12 years and, in the longer term, prevention of measles epidemics. The campaign included mass
school-based measles–mumps–rubella vaccination of children aged 5–12 years and a catch-up programme for
preschool children. More than 1.33 million children aged 5–12 years were vaccinated at school: serological
monitoring showed that 94% of such children were protected after the campaign, whereas only 84% had been
protected previously. Among preschool children aged 1–3.5 years the corresponding levels of protection were 89%
and 82%. During the six months following the campaign there was a marked reduction in the number of measles
cases among children in targeted age groups.
Keywords Measles/prevention and control; Immunization programs/organization and administration; Measles-
mumps-rubella vaccine/administration and dosage/adverse effects; School health services; Child; Child, Preschool;
Evaluation studies; Australia (source: MeSH ).
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Introduction
Live attenuated measles vaccine was first licensed in
Australia in 1968. Low coverage and outbreaks in the
early 1980s prompted a national campaign against
measles in 1987, but a survey in 1989 indicated that
coverage of young children was only 85% (1). A
measles epidemic occurred in 1993 and 1994, when
nearly 10 000 cases and 4 deaths were notified (Fig. 1).
This led to the introduction in 1994 of a second dose of
measles vaccine, in measles–mumps–rubella (MMR)
vaccine, for all children aged 10–16 years, and the
simultaneous ending of a rubella vaccination pro-
gramme for schoolgirls. Between 1994 and 1995 the
measles notification rate fell from 27 per 100 000 to 7
per 100 000, and by 1998 it had fallen to 2 per 100 000,
the lowest recorded rate since national surveillance
began in 1991 (2). In 1997, however, it emerged that
only 83% of under-2-year-olds had received MMR
vaccine (3).Moreover, the gap of ten years between the
first and second doses of vaccine had allowed the pool
of susceptible individuals to reach the annual birth
cohort of 250 000, atwhich point epidemicswere likely
to occur (4). Consequently, unless measles vaccination
coverage could be rapidly improved, repeated measles
outbreaks were to be expected.
Since 1994 a number of WHO regions have
targeted measles for either elimination or accelerated
control (5). As part of the Western Pacific Region,
Australia has focused on control, and in 1997 its
Measles Control Campaign (MCC) was announced.
This campaign, which began in June 1998, was
designed as the first stage in a longer-term strategy to
eliminate measles from the country. This paper
describes the campaign and its evaluation, including
the impact on vaccination coverage, measles im-
munity and disease incidence.
V A detailed report of the 1998 Australian Measles Control Campaign
can be obtained from the National Centre for Disease Control
website (http://immunise.health.gov.au).
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Components of the campaign
The MCC involved the following elements:
. changing the age range for the second dose of
MMR from 10–16 years to 4–5 years;
. conducting a national media and education
programme to encourage participation;
. mass school-based vaccination of children aged
5–12 years, regardless of their history of measles
or immunization;
. sending letters to parents of preschool children
aged 1–3.5 yearswhose first dose ofMMRwas due
or overdue according to the Australian Childhood
Immunisation Register (ACIR)a, encouraging
them to update their children’s vaccination status;
. sending letters to parents of all high-school
children aged 12–18 years, encouraging them to
ensure that their children had received two doses
of MMR vaccine;
. initiating two other programmes to improve
immunization uptake: a scheme linking immuni-
zation to the Childcare Assistance and the Child-
care Rebate Scheme (CRS), introduced in April,
and the General Practitioners Immunization
Incentives Scheme (GPII), introduced in July (6).
Evaluation
The evaluation of the campaign was designed and
conducted by the National Centre for Immunisation
Research and Surveillance of Vaccine Preventable
Diseases. Vaccination coverage, adverse events
associated with MMR vaccination, immunity before
and after the campaign, and the impact on the




Preschool children. ACIR (7) was used to identify
children aged 1–3.5 years whose first dose of MMR
vaccine was due or overdue. This age group was
chosen because its first dose of vaccine became due
after ACIR was established in January 1996 and
should therefore have been recorded on the register.
A reminder letter based on the health belief
model (8) was sent to parents of children whose
immunization was overdue. The effect of the letter
was determined by a) using ACIR to follow the
vaccination status of all such children and b) con-
ducting telephone interviews with a random sample
of parents of such children. The register was also
used to examine overall MMR coverage of children
aged under 7 years.
The relationship between demographic factors
and immunization status according to the parental
survey was examined by means of univariate analysis.
Pearson’s w2 test, Student’s t test andWilcoxon’s test
were used, where appropriate, to determine differ-
ences.
Primary-school children. Standardized data collec-
tion forms were completed during school visits.
Coverage was calculated as the number of students
vaccinated divided by the total number of students
enrolled. The data were analysed bymeans of SAS (9)
andExcel software (10). Pearson’sw2 test was used to
compare proportions; P-values < 0.05 were consid-
ered statistically significant.
A multistage cluster sampling method (11) was
used to select 30 schools from each state or territory
of Australia and the parents of primary-school
children for participation in surveys after the
campaign. School coordinators completed a short
written questionnaire. The effect of school char-
acteristics on vaccination coverage was determined
by univariate analysis. Mean coverage levels for each
characteristic were compared by means of ANOVA.
In each of the 240 study schools, 20 students were
randomly selected; the parents who consented to
being interviewed by telephone were asked whether
their children had been vaccinated during the
campaign as well as their attitudes to it. Univariate
analysis was performed to examine the relationship
between the children’s vaccination status and the
demographic characteristics of parents and schools.
Results
Preschool children.Reminder letters were sent to parents
of 162 143 children whose vaccination was due or
overdue; by the cut-off date of 31March 1999, ACIR
showed that 60 028 (37%) had been vaccinated and
a ACIR was the major tool used in the estimation of coverage of
preschool children. This national immunization register, established
in January 1996, aims to record the immunization status of all children
under the age of 7 years. It is operated by the Health Insurance
Commission, which also administers the national Medicare System.
Children on the register are identified from the Medicare database with
which nearly 98% of children are registered by the age of 12 months.
Notifications of immunization are received from providers either
electronically or by post and the data are updated on a daily basis.
The Health Insurance Commission uses the register to provide regular
coverage reports and to administer a recall-reminder system. ACIR
also provides national data for programme management and targeted
immunization efforts, e.g. MCC.
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that 102 115 (63%) remained unaccounted for. Of
the vaccinated children, some 40 000 (67%) had been
vaccinated previously, and 20 128 were vaccinated
after the reminder letter was sent. Of the overdue
cohort who were vaccinated, 72% received their
vaccination during the first two months of the
campaign. Older children accounted for a greater
proportion of the vaccinations given after the letter
was sent, indicating that the letter had an important
impact on those children for whom MMR vaccina-
tion was most delayed.
Of the 1601 children selected for parental
interview, 910 (57%) were successfully contacted.
The remaining 43% could not be contacted because
of problems in the electronic matching of common
names with telephone numbers. Interviewswere held
with 886 parents (55%) . There were no significant
differences between respondents and non-respon-
dents with respect to children’s ages (P= 0.06), sex
(P= 0.3), or state or territory of residence (P= 0.6).
However, a larger proportion of non-respondents
(70%) than of respondents (64%, P= 0.001) were
from metropolitan areas. Of the 886 surveyed
children, 797 had received an MMR vaccine and
700 (79%) had been vaccinated before the letter was
received. Those vaccinated after receipt of the letter
tended to live in households with only one or two
children and to have parents in paid employment.
They also tended to be younger than the childrenwho
remained unvaccinated after receipt of the letter and
to have parents who had attained higher levels of
education than those who remained unvaccinated.
According to ACIR, overall coverage of
children aged under 7 years for both MMR and the
third dose of diphtheria–tetanus–pertussis vaccine
(DTP3) remained identical and stable at around
20 000 vaccinations permonth between January 1996
and August 1998, when the number of MMR
vaccinations rose sharply to about 100 000 (Fig. 2).
Since this rise coincided with both the start of the
MCC and with two other initiatives (CRS and GPII
(6)), the contribution of individual initiatives was
difficult to determine.
Primary-school children. A total of 8783 schools in
the eight states and territories participated in the
campaign. Their combined population of eligible
children aged 5–12 years was 1.78 million. According
to data collected at the time of vaccination,
1.33 million primary-school children (75%) received
MMR vaccine within the school-based programme
between July and December 1998 (Table 1).
A questionnaire was completed by 192 (80%)
of the 240 selected schools. Information from 187 of
these schools showed that comparatively high
vaccination coverage was associated with rural
schools (P < 0.001), schools with fewer than 10%
of students who spoke a language other than English
at home (P=0.004), and schools that used verbal
reminders to encourage parents to return consent
forms (P=0.01).
Of the 3840 parents who were invited to
participate in the survey, 2225 (58%) returned the
consent form, 1860 (84%) agreed to be interviewed,
and all but 16 were contacted. No demographic
information was available for those parents who did
not participate. It was reported by 1772 parents (96%)
that their children had been vaccinated during the
campaign, 80% within the school-based programme
and 16% elsewhere, the majority by their local general
practitioner (Table 2). Vaccination outside the school-
based programme was more likely for children
attending a large school (P <0.001) or a metropolitan
school (P=0.007), but was not associated with the
type of school (government or non-government),
parental characteristics (marital status, level of educa-
tion, employment of respondent or respondent’s
partner) or the number of children in the household.
Satisfaction with the school-based programme was
expressed by 89% of parents; 87% said they would
have their children vaccinated at school in the future.
Adverse events
Methods
Adverse events following immunization (AEFIs)
withMMRvaccine during the period of the campaign
were notified to one of the three national surveillance
systems: the Adverse Drug Reactions Advisory
Committee (ADRAC)b (12), the Serious Adverse
Events Following Vaccination Surveillance Scheme
(SAEFVSS)b (12), and the campaign coordinators for
each state and territory.
AEFIs were included for analysis if they
commenced within 30 days of MMR vaccination,
were notified by 1 September 1999, and involved
children aged 5–12 years. Minor syncopal events and
anxiety reactions were excluded from the analysis. All
reported AEFIs were reviewed by a panel of six
experts, including three paediatricians, and were
classified according to definitions recommended by
the Pan American Health Organization (13). A
causality rating was assigned to each AEFI in
accordance with a classification scheme developed
by ADRAC in 1997.
Results
There were 89 AEFIs following an estimated
1.7 million doses of MMR vaccine administered
during the campaign (12), a rate of 5per 100 000 doses.
All children whowere reported to have experienced an
AEFI and who were followed up recovered without
sequelae; nine could not be followed up through the
ADRACsystembecause of confidentiality constraints.
Themost common reactions were syncopal fits
(21/89, 24%), allergic reactions not including
anaphylaxis (11/89, 12%) and other reactions
including illnesses resembling mumps and measles
(10/89, 11%). There was one report of anaphylaxis,
(i.e. less than one case per million doses delivered)
b ADRAC is responsible for the post-marketing surveillance of all
drugs, including vaccines, and receives reports from providers,
manufacturers and the community. SAEVFSS collects data on defined
serious adverse events reported by public health units. Both ADRAC
and SAEFVSS are passive surveillance schemes.
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and there were six reports of anaphylactoid reactions
(one case per 280 000). Also, there were six reports of
neurological reactions, including one case of en-
cephalopathy: in all six cases it was considered
possible that the neurological reaction was causally
related to MMR vaccination. Uncommon reactions
included arthralgia (2/89), arthritis (1/89), and
parotitis (4/89). Recovery occurred without sequelae
in the 90% of children who were followed up.
Immunity
Methods
Diagnostic laboratories throughout Australia contrib-
uted nearly 6000 residual specimens of sera, which
were tested for measles IgG as a marker of
seroprotection. Of these specimens, 2936 were
collected before and 2918 after the campaign. The
samples were stratified by age from 1 to 18 years and
the sample sizes were proportional to the state and
territory populations. Sera were not included from
subjects who were immunocompromised, had re-
ceived multiple transfusions in the previous 3 months,
or whose sera were collected specifically for the
diagnosis of measles. Age, sex and state or territory of
residence were recorded for each specimen. Samples
were centrally tested by means of a standardized
enzyme-linked immunoassay (EIA). Measles IgG
levels < 150 mIU/ml were considered negative, those
in the range 150–343 mIU/ml as equivocal, and those
> 343 mIU/ml as positive. Equivocal sera were
retested by plaque reduction neutralization (PRN)
assay. Individuals with a measles antibody level greater
than 343 mIU/ml as determined by EIA or with a
PRN titre >900 were defined as immune, i.e.
protected against infection (14).
Results
There were highly significant differences (P <0.001)
between results obtained before and after the
campaign for preschool and primary-school children
(Fig. 3). Seropositivity rose from 82% to 89% among
children aged 2–5 years and from 84% to 94% among
those aged 6–11 years. There was no significant
difference between the proportions of infants aged
1 year who were seropositive before (70%) and after
(63%) the campaign (P= 0.2). These low values
suggested that many infants failed to receive their
first dose of MMR at the scheduled age of 12 months.
The levels of seropositivity in people aged 12–18 years
before and after the campaign were not significantly
different at 89% and 91% respectively (P= 0.2).
Table 1. Proportions of primary-school children vaccinated at
school in the Australian Measles Control Campaign according
to real-time data, July–December 1998
No. of students % of enrolled
students
Students enrolled 1 781 864 100
Parental consent given 1 415 596 79.4
Students vaccinated 1 333 980 74.9
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Impact on disease
Methods
Notification data received by the National Notifiable
Diseases Surveillance System (NNDSS) were
examined to identify any impact of the campaign
on disease incidence. Notifications covering the
six months immediately after the campaign (January–
June 1999) were compared with those for the same
period of 1998 and with the average number of
notifications for the period January–June in 1996,
1997, and 1998.
Results
Of the 166 cases reported between January and
June 1998, 68 involved children aged 1–4 years
(41%), and 30 children aged 5–12 years (18%). While
there was no significant reduction in the overall
number of cases (151) in the 6 months immediately
following the campaign, there was a marked reduc-
tion in the number of cases in the age groups that
were targeted by it (Table 3). Except for the age group
19–29 years, there were fewer notifications after the
campaign than in the 3 years preceding it.
Discussion
TheMCCwas one of the largest initiatives in the area
of immunization delivery in Australia’s history. Each
of the studies in this evaluation confirmed that the
campaign was highly successful, particularly among
preschool and primary-school children. However,
12–18-year-olds, who were not specifically the
subject of media programmes, exhibited no change
in immunity status.
The primary-school parental survey indicated
that the campaign achieved 96% coverage of children
aged 5–12 years, and that 80% of them were
vaccinated at school. This demonstrated the effec-
tiveness and acceptability of the school-based
programme. The serological survey suggested that
this was likely to be an accurate estimate of coverage,
since seropositivity for the age group increased from
84% before the campaign to 94% (P < 0.001)
subsequently.
The telephone interviews with parents of
preschool children indicated that about 90% of the
children aged 1–3.5 years whose vaccinations were
overdue were vaccinated. Of these children, 79% had
been vaccinated before receipt of the reminder letter,
indicating the low sensitivity of ACIR, at the time, as a
means of identifying children whose first dose of
MMR vaccination was overdue. Despite these
limitations, this estimate is supported by the results
of the serological evaluation, showing that 89% of
children aged 1–4 years were protected after the
campaign.
The outcomes of the MCC in Australia
compare favourably with those of countries that
have conducted similar mass vaccination campaigns
in an attempt to prevent measles outbreaks or
improve measles control. For example, in 1994, as
part of a national campaign in the United Kingdom,
92% of the 7.1 million children aged 5–16 years in
England received measles–rubella vaccination (15).
Serological surveillance showed that this programme
produced a significant fall (from 15.7% to 6.6%) in
the proportion of children aged 5–16 years with low
levels of measles antibody (15). In New Zealand, a
nationwide campaign in 1997 aimed to give all
children aged 2–10 years a second dose of MMR
vaccine in order to prevent a predicted outbreak (16).
However, the outbreak commenced a month before
the start of the campaign. Although the school-based
programme was estimated to have achieved a lower
coverage (56%) than that obtained by the pro-
grammes in the United Kingdom and Australia, the
outbreak was controlled (17).
The rate of adverse events associated with
MMR vaccination during the campaign in Australia
was low (5 per 100 000) compared with the rates
Table 2. Measles–mumps–rubella vaccination status of
schoolchildren surveyed after the Australian Measles Control
Campaign (n = 1844)
Vaccination status No. of children % of surveyed
children
Vaccinated at school 1483 80.4
Vaccinated elsewhere 211 11.4
Vaccinated before campaign 68 3.7
Vaccinated after campaign 10 0.5
Total vaccinated 1772 96
Medical reason for not vaccinating 14 0.8
Opposed to vaccination 11 0.6
Intention to have child vaccinated 42 2.3
Ineligible/other 5 0.3
Total not vaccinated 72 4
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reported from the United Kingdom (14.9 per
100 000) for measles–rubella vaccine (18) and from
New Zealand (40 per 100 000) for MMR vaccine
(O. Mansoor, personal communication, 2000).
These differences may be attributable to the use of
different vaccine formulations, definitions, and
reporting systems. Underreporting is known to be a
feature of adverse event surveillance systems, but
acute and serious reactions are usually reported. It is
likely that the early recognition and management of
severe allergic reactions by trained nursing staff
reduced the incidence of true anaphylaxis during the
MCC.
The importance of the MCC can already be
measured in terms of its impact on disease incidence
in the targeted age groups. Comparison of national
notification data showed a decrease in both the
numbers and proportions of cases in the targeted age
groups after the campaign. In contrast, persons aged
19–29 years accounted for an increased proportion of
notifications, from 11% before the campaign to 51%
subsequently. For this reason, during 2001 it is
intended to target persons aged 18–30 years for
MMR immunization.
Accurate surveillance data are essential for
tracking the impact of the MCC and for planning
appropriate interventions aimed at elimination. The
serological surveys provided an objective appraisal of
the campaign. Such surveys can be used to track
community levels of immunity on a regular basis and
provide a basis for planning and evaluating future
campaigns. Surveillance and laboratory confirmation
of measles cases can also be expected to play an
increasingly important role as disease incidence
declines (19, 20).
At least in the short term, the incidence of
measles in all age groups in Australia will probably
remain low. It is now important to maintain the
momentum generated by the campaign, to identify
and manage at-risk groups, and to improve surveil-
lance methods so that the ultimate goal of measles
elimination can be reached. n
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Table 3. Comparison of measles notifications, by age group, before and after the Australian Measles
Control Campaign
Age group (years) No. notified
After campaign Before campaign Before campaign
(January–June 1999) (January–June 1998) (January–June 1996–98)
<1 23 (15)a 45 (27) 82 (21)
1–4 21 (14) 68 (41) 127 (33)
5–12 11 (7.3) 30 (18) 66 (17)
13–18 8 (5.3) 3 (1.8) 19 (4.9)
19–29 77 (51) 18 (11) 70 (18)
530 11 (7.3) 2 (1.2) 23 (5.9)
Total 151 (100) 166 (100) 387 (100)
a Figures in parentheses are % of notifications in each age group.
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Re´sume´
La campagne australienne de lutte contre la rougeole, 1998
La campagne australienne de lutte contre la rougeole
re´alise´e en 1998 avait pour but l’ame´lioration de la
couverture vaccinale des enfants de 1 a` 12 ans et, a` long
terme, la pre´vention des e´pide´mies de rougeole. Elle
comportait la vaccination de masse en milieu scolaire des
enfants de 5 a` 12 ans par le vaccin antirougeoleux-
antiourlien-antirube´oleux, ainsi qu’un programme de
rattrapage destine´ aux enfants d’aˆge pre´scolaire. Plus de
1,33 million d’enfants de 5 a` 12 ans ont e´te´ vaccine´s a`
l’e´cole : le controˆle se´rologique montre que 94 % de ces
enfants ont e´te´ prote´ge´s apre`s la campagne, alors que
84 % seulement avaient e´te´ prote´ge´s ante´rieurement. La
protection des enfants d’aˆge pre´scolaire de 1 a` 3,5 ans
e´tait respectivement de 89 % et 82 %. Pendant les
six mois qui ont suivi la campagne, le nombre de cas
de rougeole chez les enfants des groupes cibles e´tait
conside´rablement re´duit.
Resumen
La campan˜a de lucha contra el sarampio´n en Australia en 1998
La campan˜a de lucha contra el sarampio´n llevada a cabo
en Australia en 1998 tenı´a como objetivo mejorar la
cobertura inmunitaria entre los nin˜os de 1 a 12 an˜os y, a
largo plazo, prevenir las epidemias de sarampio´n. La
campan˜a incluı´a la vacunacio´n masiva en las escuelas de
los nin˜os de 5 a 12 an˜os contra el sarampio´n-
parotiditisrube´ola y un programa de vacunacio´n de
seguimiento destinado a nin˜os en edad preescolar. Ma´s
de 1,33 millones de nin˜os de 5 a 12 an˜os fueron
vacunados en la escuela: la vigilancia serolo´gica mostro´
que el 94% de esos nin˜os quedaron protegidos despue´s
de la campan˜a, mientras que so´lo un 84% habı´a gozado
de proteccio´n anteriormente. Entre los nin˜os en edad
preescolar, 1-3,5 an˜os, los niveles correspondientes de
proteccio´n fueron del 89% y el 82%. Durante los seis
meses que siguieron a la campan˜a se observo´ una
marcada reduccio´n de los casos de sarampio´n entre los
nin˜os de los grupos de edad en cuestio´n.
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